PT-141 (Bremelanotide) research guide for Katse. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
PT-141 (Bremelanotide) isn't stocked on pharmacy shelves in Katse or most other cities — it's a research compound supplied via a dedicated online market. The upside of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than any local market ever offers. Separating quality PT-141 (Bremelanotide) from the rest of the market comes down to three things: an HPLC chromatogram confirming ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the standards covered in this guide apply whether you are in Katse or anywhere else.
What Studies Say About PT-141 (Bremelanotide)
The melanocortin receptor family (MC1R through MC5R) mediates a diverse range of physiological functions, and research peptides like Melanotan-2 and PT-141 (Bremelanotide) act on different receptor subtypes with different research applications. MT-2 has broad melanocortin receptor activity and has been studied for pigmentation (MC1R), appetite suppression (MC4R), and other endpoints. PT-141 is a more specific MC3R/MC4R agonist studied primarily for CNS-mediated effects. For researchers in Katse designing experiments with PT-141 (Bremelanotide), the specific receptor binding profile determines which outcomes are mechanistically attributable to the compound and which require additional explanation.
Where to Buy PT-141 (Bremelanotide) — A Researcher's Guide
Assessing PT-141 (Bremelanotide) vendors requires starting from the COA: locate the batch-specific certificate before placing an order, not after. A COA for PT-141 (Bremelanotide) should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. For Katse researchers evaluating new suppliers: a modest first purchase to test the product before scaling up your order is the accepted approach among experienced researchers. Bacteriostatic water is the appropriate reconstitution medium for PT-141 (Bremelanotide) — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 30 days refrigerated.
Order PT-141 (Bremelanotide) — ships to Katse
COA-verified · International tracking · Research grade
PT-141 (Bremelanotide) is sold for research purposes only and is not approved for human use by the FDA or comparable health authorities — all information here is educational. Proper handling of PT-141 (Bremelanotide) requires sterile reconstitution technique — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and cold chain maintenance from receipt through use. The main safety concern arising from sourcing in PT-141 (Bremelanotide) research is bacterial endotoxin from low-quality material — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. The research literature on PT-141 (Bremelanotide) should be read critically before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
